Last reviewed · How we verify
CMAB015
CMAB015 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
At a glance
| Generic name | CMAB015 |
|---|---|
| Sponsor | Taizhou Mabtech Pharmaceutical Co.,Ltd |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of CMAB015 has not been widely disclosed in public literature, it is developed as an immunotherapeutic monoclonal antibody by Taizhou Mabtech Pharmaceutical. As a Phase 3 candidate, it is likely designed to modulate immune responses against cancer cells, potentially through checkpoint inhibition or direct tumor antigen targeting.
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers (PHASE1)
- Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CMAB015 CI brief — competitive landscape report
- CMAB015 updates RSS · CI watch RSS
- Taizhou Mabtech Pharmaceutical Co.,Ltd portfolio CI